Sobi exercises opt-in right for Alprolix®
(Thomson Reuters ONE) -
Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) announced today that the
company has decided to exercise its opt-in right to take over final development
and commercialisation of Alprolix (rFIXFc) for the territory composed of Europe,
North Africa, Russia and certain Middle Eastern markets. Alprolix is a
recombinant factor IX Fc fusion protein product candidate for the treatment of
haemophilia B. Sobi will make a payment to Biogen of USD 10 million, which will
be held in escrow pending the EU regulatory approval of Alprolix.
"This is an important milestone for Sobi and the result of a strong
collaboration between Sobi and Biogen," said Geoffrey McDonough, CEO at Sobi.
"We are looking forward to the possibility of making this innovative treatment
available for people with haemophilia B upon approval in our territory,
increasing treatment choices and advancing patient care for the haemophilia
community."
Sobi and Biogen are collaboration partners in the development and
commercialisation of Alprolix for haemophilia B. Sobi has an opt-in right to
assume final development and commercialisation of Alprolix for the Sobi
territory. Biogen has led development for Alprolix, has manufacturing rights,
and has commercialisation rights in North America and all other regions in the
world excluding the Sobi territory.
On 26 June 2015 Sobi and Biogen announced that the European Medicines Agency
(EMA) had validated the Marketing Authorisation Application (MAA) for Alprolix.
The validation of the MAA initiated the EMA's review process. Alprolix
[Coagulation Factor IX (Recombinant), Fc Fusion Protein] is approved for the
treatment of haemophilia B in the U.S., Canada, Australia, and Japan.
---
About Haemophilia B
The World Federation of Hemophilia global survey conducted in 2013 estimates
that approximately 28,430 people are currently diagnosed with haemophilia B
worldwide. It is caused by having substantially reduced or no factor IX
activity, which is needed for normal blood clotting. People with haemophilia B
experience bleeding episodes that cause pain, irreversible joint damage, and
life-threatening haemorrhages. Prophylactic infusions of factor IX temporarily
replace clotting factors necessary to control bleeding and prevent new bleeding
episodes.
About Alprolix
Alprolix is a recombinant, clotting factor therapy developed for haemophilia B
by fusing factor IX to the Fc portion of immunoglobulin G subclass 1, or IgG1 (a
protein commonly found in the body). It is believed that this enables Alprolix
to use a naturally occurring pathway to prolong the time the therapy remains in
the body. While Fc fusion has been used for more than 15 years, Biogen and Sobi
are the only companies to apply it in haemophilia.
About the Biogen and Sobi Collaboration
To exercise its opt-in right to take over final development and
commercialization of Alprolix for its territory, Sobi will now make a payment
into escrow of USD 10 million. Upon EU regulatory approval of Alprolix, Sobi
will be liable to repay approximately half of the development and manufacturing
costs for Alprolix incurred by Biogen, as well as for additional investments.
Sobi estimates the total repayment obligation to reach approximately USD 201
million.
The cross-royalty and collaboration structure is described in detail in the Sobi
press release dated 2012-02-06 "Sobi's agreement with Biogen Idec regarding
long-lasting rFVIIIFc and rFIXFc hemophilia programs".
About Sobi
Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on Haemophilia, Inflammation and Genetic diseases. We also market a
portfolio of specialty and rare disease products for partner companies across
Europe, the Middle East, North Africa and Russia. Sobi is a pioneer in
biotechnology with world-class capabilities in protein biochemistry and
biologics manufacturing. In 2014, Sobi had total revenues of SEK 2.6 billion
(USD 380 M) and about 600 employees. The share (STO: SOBI) is listed on NASDAQ
OMX Stockholm. More information is available at www.sobi.com.
For more information please contact
Media relations Investor relations
Oskar Bosson, Head of Jörgen Winroth, Vice President, Head of Investor
Communications Relations
T: +46 70 410 71 80 T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135
oskar.bosson(at)sobi.com jorgen.winroth(at)sobi.com
026e_Alprolix opt-in:
http://hugin.info/134557/R/1939162/699462.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via GlobeNewswire
[HUG#1939162]
Unternehmensinformation / Kurzprofil:
Datum: 16.07.2015 - 07:59 Uhr
Sprache: Deutsch
News-ID 407215
Anzahl Zeichen: 5755
contact information:
Town:
Stockholm
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 185 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Sobi exercises opt-in right for Alprolix®"
steht unter der journalistisch-redaktionellen Verantwortung von
Swedish Orphan Biovitrum AB (publ) (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
